Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 8906SC

8906SC 25 µg (With Carrier)
8906SF 25 µg (Carrier Free)
8906LC 100 µg (With Carrier)
8906LF 100 µg (Carrier Free)

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant human IL-17F (hIL-17F) Arg31-Gln163 (Accession #NP_443104) was expressed in human 293 cells at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-17F. All lots are greater than 98% pure.


Molecular Formula:

Recombinant hIL-17F contains no "tags" and the nonglycosylated protein has a calculated MW of 14,903. DTT-reduced protein migrates as a 22 kDa polypeptide. Lower mobility in SDS-PAGE is due to glycosylation. The non-reduced cystine-linked homodimer migrates as a 38 kDa protein. The expected amino-terminal RKIPK of recombinant hIL-17F was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant hIL-17F was determined by its ability to induce mouse IL-6 production by 3T3 MEFs WT. The ED50 of each lot is between 30-80 ng/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1 μg hIL-17F.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-17F. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

IL-17F is a cystine-linked homodimeric pro-inflammatory cytokine produced by TH17 cells, a distinct CD4+ T cell subset (1). IL-17F induces the production of pro-inflammatory cytokines, antimicrobial peptides, and neutrophil chemoattractants such as IL-6, β-defensin, IL-8, CXCL1, and CXCL6 (1,2). As a result, IL-17F may provide an important link between adaptive and the innate immunity. IL-17F binds with high affinity to IL-17RC, expressed primarily in non-hematopoietic tissues, and with lesser affinity to IL-17RA, which is expressed in hematopoietic tissues (3). IL-17F binding activates the ERK1/2 MAP kinase and NF-κB pathways (1,4). IL-17F appears to be involved in mucosal immunity against bacterial infections and possibly some autoimmune conditions (1,5,6).


1.  Kuestner, R.E. et al. (2007) J Immunol 179, 5462-73.

2.  Kawaguchi, M. et al. (2002) J Biol Chem 277, 15229-32.

3.  Ishigame, H. et al. (2009) Immunity 30, 108-19.

4.  Kolls, J.K. and Lindén, A. (2004) Immunity 21, 467-76.

5.  Liang, S.C. et al. (2006) J Exp Med 203, 2271-9.

6.  Zrioual, S. et al. (2009) J Immunol 182, 3112-20.


Entrez-Gene Id 112744
Swiss-Prot Acc. Q96PD4


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.